Deborah Strahs
Welcome,         Profile    Billing    Logout  
 8 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Choueiri, Toni
SAVOIR, NCT03091192 / 2016-004108-73: Savolitinib vs. Sunitinib in MET-driven PRCC.

Checkmark From SAVIOR trial vs sunitinib in patients with MET-driven papillary RCC
May 2020 - May 2020: From SAVIOR trial vs sunitinib in patients with MET-driven papillary RCC
Active, not recruiting
3
60
Europe, US, RoW
Savolitinib, AZD6094 (HMPL-504)/Volitinib, Sunitinib
AstraZeneca, Hutchison Medipharma Limited
Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
08/19
12/25
SAMETA, NCT05043090 / 2021-000336-55: Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Active, not recruiting
3
147
Europe, Canada, US, RoW
savolitinib, AZD6094, HMPL-504, volitinib, durvalumab, MEDI4736, sunitinib, Sutent, SU11248
AstraZeneca, AstraZeneca AB
Papillary Renal Cell Carcinoma
06/25
06/26
NCT02724878: Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Completed
2
65
US
Bevacizumab, Avastin, Atezolizumab, RG-7446
Dana-Farber Cancer Institute, Genentech, Inc.
Advanced Non-Clear Cell Kidney Cancer
11/19
12/24
OMNIVORE, NCT03203473: Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC ( Study)

Checkmark From OMNIVORE study in combination with Yervoy for advanced RCC
Nov 2020 - Nov 2020: From OMNIVORE study in combination with Yervoy for advanced RCC
Checkmark From OMNIVORE study in combination with Yervoy for advanced RCC
May 2020 - May 2020: From OMNIVORE study in combination with Yervoy for advanced RCC
Checkmark From OMNIVORE study in combination with Opdivo for advanced RCC
More
Active, not recruiting
2
85
US
Ipilimumab, Yervoy, Nivolumab, Opdivo
Toni Choueiri, MD, Bristol-Myers Squibb
Renal Cancer
11/21
12/25
NKT2152-202, NCT05935748: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Active, not recruiting
2
172
US
NKT2152, palbociclib, IBRANCE®, sasanlimab
NiKang Therapeutics, Inc., Pfizer
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
06/25
06/26
NKT2152-101, NCT05119335: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
1/2
128
US
Oral NKT2152
NiKang Therapeutics, Inc.
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
05/25
09/26
NCT04627064: ABEMA Alone or in COMBO With MK-6482

Completed
1
11
US
Abemaciclib, Verzenio, MK-6482, HIF-2α inhibitor
Dana-Farber Cancer Institute, Eli Lilly and Company
Clear Cell Renal Cell Carcinoma
02/24
08/24
NCT02950766: NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Active, not recruiting
1
19
US
NeoVax, neoantigen vaccine, Ipilimumab, Yervoy
Patrick Ott, MD, PhD, Bristol-Myers Squibb, Oncovir, Inc.
Kidney Cancer
01/26
05/30
Strahs, Deborah
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Choueiri, Toni
SAVOIR, NCT03091192 / 2016-004108-73: Savolitinib vs. Sunitinib in MET-driven PRCC.

Checkmark From SAVIOR trial vs sunitinib in patients with MET-driven papillary RCC
May 2020 - May 2020: From SAVIOR trial vs sunitinib in patients with MET-driven papillary RCC
Active, not recruiting
3
60
Europe, US, RoW
Savolitinib, AZD6094 (HMPL-504)/Volitinib, Sunitinib
AstraZeneca, Hutchison Medipharma Limited
Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Urologic Neoplasms, Kidney Diseases, Neoplasms by Site, Enzyme Inhibitors, Protein Kinase Inhibitors
08/19
12/25
SAMETA, NCT05043090 / 2021-000336-55: Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Active, not recruiting
3
147
Europe, Canada, US, RoW
savolitinib, AZD6094, HMPL-504, volitinib, durvalumab, MEDI4736, sunitinib, Sutent, SU11248
AstraZeneca, AstraZeneca AB
Papillary Renal Cell Carcinoma
06/25
06/26
NCT02724878: Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Completed
2
65
US
Bevacizumab, Avastin, Atezolizumab, RG-7446
Dana-Farber Cancer Institute, Genentech, Inc.
Advanced Non-Clear Cell Kidney Cancer
11/19
12/24
OMNIVORE, NCT03203473: Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC ( Study)

Checkmark From OMNIVORE study in combination with Yervoy for advanced RCC
Nov 2020 - Nov 2020: From OMNIVORE study in combination with Yervoy for advanced RCC
Checkmark From OMNIVORE study in combination with Yervoy for advanced RCC
May 2020 - May 2020: From OMNIVORE study in combination with Yervoy for advanced RCC
Checkmark From OMNIVORE study in combination with Opdivo for advanced RCC
More
Active, not recruiting
2
85
US
Ipilimumab, Yervoy, Nivolumab, Opdivo
Toni Choueiri, MD, Bristol-Myers Squibb
Renal Cancer
11/21
12/25
NKT2152-202, NCT05935748: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Active, not recruiting
2
172
US
NKT2152, palbociclib, IBRANCE®, sasanlimab
NiKang Therapeutics, Inc., Pfizer
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
06/25
06/26
NKT2152-101, NCT05119335: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
1/2
128
US
Oral NKT2152
NiKang Therapeutics, Inc.
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
05/25
09/26
NCT04627064: ABEMA Alone or in COMBO With MK-6482

Completed
1
11
US
Abemaciclib, Verzenio, MK-6482, HIF-2α inhibitor
Dana-Farber Cancer Institute, Eli Lilly and Company
Clear Cell Renal Cell Carcinoma
02/24
08/24
NCT02950766: NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Active, not recruiting
1
19
US
NeoVax, neoantigen vaccine, Ipilimumab, Yervoy
Patrick Ott, MD, PhD, Bristol-Myers Squibb, Oncovir, Inc.
Kidney Cancer
01/26
05/30
Strahs, Deborah
No trials found

Download Options